Skip to main content

Table 3 Antibiotic progression in patients with Staphylococcus aureus bloodstream infection with antibiotic history (n = 45)

From: Can the Xpert MRSA/SA BC assay be used as an antimicrobial stewardship tool? A prospective assay validation and descriptive impact assessment study in a South African setting

  Methicillin-sensitive S. aureus (n = 34) Methicillin-resistant S. aureus (n = 11)
  Empiric
Choice
n (%) [95% CI]
In response to Gram result
n (%) [95% CI]
On culture result
n (%) [95% CI]
Empiric choice
n (%) [95% CI]
In response to Gram result
n (%) [95% CI]
On culture result
n (%) [95% CI]
Patients receiving an agent with activity against the organism isolateda 27 (79.4) [61.6–90.7] 29 (85.3) [68.2–94.5] 34 (100) [87.4–100] 3 (27.3) [7.3–60.7%] 5 (45.5) [18.1–75.4] 11 (100.0) [67.9–100.0]
  1. MRSA Methicillin-resistant Staphylococcus aureus, MSSA Methicillin-sensitive Staphylococcus aureus, CI Confidence interval
  2. aEmpiric cover for MSSA included any agent with anti-MSSA activity, including ceftriaxone/cefotaxime for MSSA. Empiric cover for MRSA consisted of vancomycin in our setting